Welcome to our dedicated page for CELLBXHEALTH PLC news (Ticker: ANPCY), a resource for investors and traders seeking the latest updates and insights on CELLBXHEALTH PLC stock.
CelLBxHealth plc, formerly known as ANGLE plc and represented in the United States as ANGLE PLC S/ADR (symbol ANPCY), regularly issues news updates that describe its progress in circulating tumour cell (CTC) intelligence and liquid biopsy. Company announcements highlight developments around its Parsortix® platform, collaborations with pharmaceutical and medtech partners, and strategic decisions affecting its business direction and branding.
News items often cover clinical and scientific milestones, such as proof-of-concept studies in indications like glioblastoma and integrations of the Parsortix workflow with established diagnostic platforms, including Roche Tissue Diagnostics’ BenchMark ULTRA system. Releases also describe participation in major oncology and drug development conferences, where the company presents data on CTC detection, biomarker analysis and potential applications in areas such as antibody-drug conjugate development.
Investors and researchers following ANPCY-related news will also see updates on commercial contracts and collaborations. The company has reported completing contracts with large pharmaceutical companies, ongoing services agreements with biopharma partners, and a collaboration with Myriad Genetics to adapt an existing tissue-based cancer test to a CTC-based format using Parsortix. Interim results and strategy updates provide context on revenue mix between pharma services and product sales, as well as commentary on external market conditions.
Corporate governance and board or management changes are another recurring theme. Recent announcements include the transition from ANGLE plc to CelLBxHealth plc, the appointment of an Executive Chairman, subsequent changes to the board, and later the appointment of a Chief Executive Officer and additional non-executive directors. These updates are presented alongside information on funding plans and cash runway.
For readers tracking ANPCY, the news stream offers a consolidated view of how CelLBxHealth is advancing CTC-based technologies, engaging with global partners, and refining its strategy in response to scientific opportunities and market conditions.
ANGLE plc has completed patient enrolment in a 200-patient ovarian cancer clinical verification study at the University of Rochester. The study evaluates the effectiveness of ANGLE's Parsortix system and HyCEAD platform for detecting ovarian cancer through a simple blood test. The study aims to finalize data by Q2 2021 and report results in Q4 2021. If successful, ANGLE plans to launch the test as a laboratory-developed test (LDT) by year-end, potentially addressing a market worth up to $1.8 billion in the U.S. alone.
ANGLE has announced a significant contract potentially worth US$1.2 million over 18 months with a major pharmaceutical company to utilize its Parsortix system.
This contract marks the first large-scale application of Parsortix in cancer drug trials, focusing on prostate cancer and other solid tumors. The system, which captures circulating tumor cells (CTCs) for analysis, enables ongoing monitoring of patients during clinical trials, surpassing traditional tissue biopsies in providing vital insights into cancer treatment.
ANGLE plc (OTCQX:ANPCY), a leader in liquid biopsy technology, will release its preliminary results for the year ending December 31, 2020, on April 29, 2021. A virtual meeting for analysts will occur at 10:00 am BST on the same day. The Parsortix system, their flagship technology, allows for non-invasive cancer analysis and has demonstrated a high accuracy in clinical studies. ANGLE's ongoing advancements include FDA submissions for regulatory clearance and collaborations with major healthcare entities to expand its market presence.
ANGLE plc announced its Parsortix system's capabilities showcased at the AACR 2021 conference. Two poster presentations highlighted the efficacy of new assays: one for circulating tumor cells (CTCs) detection in cancer (showing 25-38% of CTCs had mesenchymal markers), and another assessing PD-L1 status in patients, indicating potential for personalized immunotherapy. The global PD-L1 inhibitor market is projected to reach $22 billion, growing over 40% annually. ANGLE is pursuing partnerships for clinical trials and has established labs in the UK and US.
ANGLE plc (OTCQX:ANPCY) has successfully launched its clinical services laboratories in Guildford, UK, and Plymouth Meeting, PA, earlier than planned. These labs will enhance the commercialization of the Parsortix system, allowing for circulating tumor cell (CTC) analysis in cancer drug trials. With over 2,000 relevant interventional trials and 300,000 patients registered, ANGLE aims to be a key player. Both labs seek ISO15189 and CLIA accreditations, with the Ovarian Cancer Pelvic Mass Triage assay being targeted as the first Laboratory Developed Test.
ANGLE plc provides an update on its submission for FDA clearance of the Parsortix PC1 system. The FDA issued an Additional Information Request (AIR), which was anticipated and is part of the De Novo clearance process. ANGLE plans to respond by early May, with no need for new patient samples. However, due to ongoing COVID-19 priorities, FDA review times are slower, pushing expected clearance to the second half of 2021. Despite these challenges, ANGLE continues progress in establishing clinical laboratories and developing a new pharma services business.
Summary not available.
ANGLE plc's Parsortix system is showcased as a significant advancement in monitoring non-small cell lung cancer (NSCLC) patient responses to treatment. A study from the National and Kapodistrian University of Athens demonstrated how the system can track changes in circulating tumor cell (CTC) gene expression in patients treated with Osimertinib. Notably, the study revealed that 60% of patients exhibited mesenchymal/epithelial to mesenchymal transition (EMT) biomarkers at baseline, increasing to 80% post-treatment. ANGLE aims to leverage these findings to enhance its new 'pharma services' offering, providing critical insights for cancer drug trials.
ANGLE plc (AIM:AGL) announced its interim results for the six months ending June 30, 2020, reporting revenue of £0.2 million, down from £0.4 million in H1 2019. The loss for the period remained at £4.8 million. The cash balance as of June 30, 2020, was £13.8 million, down from £18.8 million at the end of 2019. The company completed its De Novo FDA submission for the Parsortix system aimed at metastatic breast cancer, with an expected FDA clearance in Q2 2021. Post-period fundraising raised £19.6 million to support ongoing commercialization efforts.
ANGLE plc has successfully completed the FDA's administrative review for its Parsortix system, seeking clearance for use with metastatic breast cancer. The full Class II De Novo submission aims for FDA clearance potentially by Q2 CY21. This submission follows five years of development and extensive documentation. The FDA has 150 days to make a decision post-submission acceptance. ANGLE's technology has the potential to be the first of its kind to capture intact circulating tumor cells from blood for analysis, marking a significant advancement in non-invasive cancer diagnostics.